TargetBeta
FCGRT
Fc gamma receptor and transporter · also FcgammaRn, FcRn · C1-set domain containing
4 programs in company-led studies act on FCGRT, from 4 companies: 2 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| efgartigimod alfarule | argenx | phase 4 | 4817 running | – | ChEMBL |
| rozanolixizumabrule | UCB | phase 4 | 235 running | – | ChEMBL |
| nipocalimabrule | Johnson & Johnson | phase 3 | 2411 running | – | ChEMBL |
| batoclimabrule | Immunovant Sciences | phase 3 | 180 running | – | ChEMBL |
Conditions their studies are in
- Myasthenia Gravis, 4 programs
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 3 programs
- Purpura, Thrombocytopenic, Idiopathic, 3 programs
- Graves Disease, 2 programs
- Arthritis, Rheumatoid, 1 program
- Fibromyalgia, 1 program
- Graves Ophthalmopathy, 1 program
- Lupus Erythematosus, Systemic, 1 program
- Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, 1 program
- Myositis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 15, 2026nipocalimab · Johnson & Johnson · phase 3 · NCT05327114
- Mar 2027efgartigimod alfa · argenx · phase 4 · NCT04833894
- May 6, 2027rozanolixizumab · UCB · phase 4 · NCT05063162
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.